April 26, 2022 07:17 AM EDT

In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it promises a turnaround

Amber Tong

For years, NKTR-214 — also known as bempeg, short for bempegaldesleukin — was the star of the show at Nektar Therapeutics, with the promise of targeting IL …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it promises a turnaround

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Intellia to cut workforce by 27%, plans commercialization of first CRISPR therapy in 2027

Lilly ventures into pulmonary fibrosis with startup Mediar

John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief

With $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring

Another biotech scoops up asset from China-based Keymed and nabs $180M

Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs

In wake of IL-2 shut­down, Nek­tar lets go of 500+ staffers as it promis­es a turn­around

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it promises a turnaround